Short answer
Cencora (COR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Cencora announced fiscal fourth-quarter and full-year 2026 earnings for the period ended September 30, 2026.
Cencora 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Cencora announced fiscal fourth-quarter and full-year 2026 earnings for the period ended September 30, 2026
- Earnings release issued November 4, 2026, with financial results and management commentary in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Conference call covers fiscal Q4 and full-year results ended September 30, 2026
- Investor presentation and webcast available at investor.cencora.com
- Results discussion may provide management outlook and strategic updates beyond reported financials
Item EX-99.1 · Exhibit EX-99.1
- Q4 revenue $88.4B, up 5.5%, while adjusted EPS rose 21.4% to $4.66, showing strong earnings conversion
- Fiscal 2026 adjusted EPS $17.97, up 12.3%, supported by 20.0% adjusted gross-profit growth and OneOncology contribution
- Fiscal 2027 adjusted EPS target $19.40 to $19.75, implying 8% to 10% growth, with adjusted free cash flow expected near $3.5B
- New segments target faster Specialty Pharmaceutical and Provider Services growth, including 18% to 21% adjusted operating-income growth
- Quarterly dividend increased 10% to $0.66 per share, while Profarma sale and planned MWI transaction reshape the portfolio
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cencora 8-K filings
Get the next COR 8-K as it lands
Follow COR for push alerts, or ask the research agent what this filing means.